SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Rating of “Buy” from Analysts

SI-BONE, Inc. (NASDAQ:SIBNGet Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $27.29.

Several research analysts have issued reports on SIBN shares. Needham & Company LLC reissued a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Piper Sandler initiated coverage on SI-BONE in a research report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 price target on the stock. Morgan Stanley decreased their price objective on SI-BONE from $26.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, May 7th. Truist Financial reissued a “buy” rating and issued a $24.00 target price (down previously from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a report on Tuesday, May 7th.

View Our Latest Report on SI-BONE

SI-BONE Trading Up 4.3 %

Shares of NASDAQ:SIBN opened at $14.05 on Friday. SI-BONE has a 52 week low of $13.34 and a 52 week high of $29.51. The company’s 50 day moving average is $14.95 and its two-hundred day moving average is $17.67. The company has a market cap of $579.00 million, a PE ratio of -12.89 and a beta of 1.24. The company has a current ratio of 9.76, a quick ratio of 8.75 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBNGet Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $37.87 million for the quarter, compared to the consensus estimate of $36.45 million. SI-BONE had a negative return on equity of 25.14% and a negative net margin of 29.93%. Equities analysts predict that SI-BONE will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,941 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.10, for a total transaction of $59,509.10. Following the transaction, the insider now owns 247,592 shares in the company, valued at $3,738,639.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other SI-BONE news, insider Anthony J. Recupero sold 3,941 shares of SI-BONE stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.10, for a total transaction of $59,509.10. Following the sale, the insider now directly owns 247,592 shares in the company, valued at approximately $3,738,639.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 2,425 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares of the company’s stock, valued at approximately $3,175,222.20. The disclosure for this sale can be found here. Insiders sold 19,868 shares of company stock valued at $310,659 over the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC raised its stake in SI-BONE by 63.2% during the 3rd quarter. Barclays PLC now owns 24,286 shares of the company’s stock valued at $516,000 after acquiring an additional 9,402 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of SI-BONE by 17.7% during the third quarter. New York State Common Retirement Fund now owns 376,943 shares of the company’s stock valued at $8,006,000 after purchasing an additional 56,630 shares during the period. Moody Aldrich Partners LLC increased its holdings in shares of SI-BONE by 4.1% during the third quarter. Moody Aldrich Partners LLC now owns 171,748 shares of the company’s stock valued at $3,648,000 after purchasing an additional 6,823 shares during the period. RiverPark Advisors LLC bought a new stake in shares of SI-BONE during the third quarter valued at about $55,000. Finally, Swiss National Bank lifted its holdings in SI-BONE by 1.1% in the third quarter. Swiss National Bank now owns 76,600 shares of the company’s stock worth $1,627,000 after purchasing an additional 800 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Company Profile

(Get Free Report

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Recommended Stories

Analyst Recommendations for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.